Clinical Trials Browser

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05883956 2025-03-20

PREFER-HMA

Phase 3 Active not recruiting

13 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Patient Preference

NCT05583552 2025-03-14

IMpress

Phase 2 Active not recruiting

46 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04623944 2024-12-27

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

Phase 1 Active not recruiting

61 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03927261 2024-11-08

PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS

Phase 1 Active not recruiting

88 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01744223 2022-07-12

Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

Phase 1/2 Active not recruiting

36 enrolled

LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Lymphoma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02477878 2022-07-12

Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant

Phase 1 Active not recruiting

10 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Hematologic Neoplasms

NCT03301168 2022-07-12

Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant

Phase 1/2 Active not recruiting

120 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Primary Immunodeficiency Diseases, Cytopenia, Anemia, Aplastic, Leukemia, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Osteopetrosis, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03459170 2022-07-12

Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant

Phase 1 Active not recruiting

15 enrolled

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Neoplasm, Residual, Hematologic Neoplasms

Clinical Trials

ACROBAT

Orca-T

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

LIMBER

BEXMAB

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

TWT-202

Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

PREFER-HMA

IMpress

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS

Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant

Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant

Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant